ReviewBioMed research international2013
Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 383 citations in OpenAlex.
- Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.Journal of clinical pharmacology · 2018Trial
- Review
- Antifungal Effects of Terminalia arjuna Fruit Extract on Multidrug-Resistant Candida auris: An In Vitro Study.Cureus · 2026Article
- Review
- Emergence of Candida (Candidozyma) auris in Minas Gerais, Brazil: Genomic Surveillance to Guide Rapid Public Health Responses.Mycoses · 2026Article
- Synthesis of mono- and di-(Frontiers in chemistry · 2026Article
- Nanotechnology-driven strategies to overcome azole resistance inFrontiers in plant science · 2026Review
- Calcium transport systems as virulence determinants: Mechanistic insights into fungal pathogenicity and antifungal resistance.Virulence · 2025Review
- A study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand.Scientific reports · 2025Article
- Article
- Antimicrobial Peptides Act-6 and Act 8-20 Derived from Scarabaeidae Cecropins Exhibit Differential Antifungal Activity.Journal of fungi (Basel, Switzerland) · 2025Article
- Article
- Emerging Treatments in Neonatal Fungal Infections: Progress and Prospects.Paediatric drugs · 2025Review
- Epidemiology, Risk Factors and Clinical Outcome of Candidaemia:Sultan Qaboos University medical journal · 2025Observational
- Exponential Clonal Expansion of 5-Fluorocytosine-Resistant Candida tropicalis and New Insights into Underlying Molecular Mechanisms.Emerging infectious diseases · 2025Article
- Synthesis of 2-Amino-4, 5-Diarylthiazole Derivatives and Evaluation of Their Anti-Molecules (Basel, Switzerland) · 2025Article
- Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Effect of the Incorporation of an Innovative Monomer with a Quaternary Ammonium Group into a Temporary Soft Liner on Its Biological and Physicochemical Properties.Molecules (Basel, Switzerland) · 2025Article
- Celastrol boosts fluconazole efficacy against vaginal candidiasis: in vitro and in vivo evidence.AMB Express · 2025Article
- First Report ofInfection and drug resistance · 2025Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Candida includes about 200 different species, but only a few species are human opportunistic pathogens and cause infections when the host becomes debilitated or immunocompromised. Candida infections can be superficial or invasive. Superficial infections often affect the skin or mucous membranes and can be treated successfully with topical antifungal drugs. However, invasive fungal infections are often life-threatening, probably due to inefficient diagnostic methods and inappropriate initial antifungal therapies. Here, we briefly review our current knowledge of pathogenic species of the genus Candida and yeast infection causes and then focus on current antifungal drugs and resistance mechanisms. An overview of new therapeutic alternatives for the treatment of Candida infections is also provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.